Stock comparison
LeMaitre Vascular
Novo Nordisk A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
NVO
Novo Nordisk A/S
Market cap
$199.79B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | NVO | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 65B | LMAT |
| Benjamin Graham | 89A | 61C | LMAT |
| Philip Fisher | 81C | 73B | LMAT |
| Peter Lynch | 67B | 57C | LMAT |
| Joel Greenblatt | 56D | 56C | Tie |
| Charlie Munger | 68D | 76B | NVO |
| Terry Smith | 69D | 72C | NVO |
Side-by-side metrics
| Metric | LMAT | NVO |
|---|---|---|
| Market cap | $2.23B | $199.79B |
| P/E (TTM) | 37.1x | 10.4x |
| EV/EBIT | 36.6x | 10.9x |
| ROIC (TTM) | 9.43% | 32.2% |
| Gross margin | 72.39% | 81.85% |
| Net margin | 24.35% | 37.2% |
| Revenue CAGR 5y | 12.75% | 21.72% |
| EPS CAGR 5y | 19.04% | 22.03% |
| Debt / Equity | 0.5x | 0.7x |
| Dividend yield | 0.84% | 4.09% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Debt / Equity0.5xvs 0.7x+35%
NVO leads on
- Market cap$199.79Bvs $2.23B+99%
- Dividend yield4.09%vs 0.84%+80%
- P/E (TTM)10.4xvs 37.1x+72%
- ROIC (TTM)32.2%vs 9.43%+71%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.